U.S. Metals and Mining Stock News

Teva Pharmaceutical Industries (NYSE:TEVA) has been back in the spotlight after CEO Richard D. Francis discussed the company’s Pivot to Growth plan at the Leerink Global Healthcare Conference in Miami. See our latest analysis for Teva Pharmaceutical Industries. The recent pullback, with a 9.2% 30 day share price return and 6.7% 7 day share price return, comes after a strong run that leaves Teva on a 114.7% one year total shareholder return and a 252.4% three year total shareholder return...

BETA Technologies (BETA) has just posted its FY 2025 third quarter numbers, with revenue of US$8.9 million, basic EPS of a US$9.83 loss, and trailing twelve month revenue of US$28.9 million alongside a trailing EPS loss of US$15.80. Over the past year, the company has seen revenue rise from US$15.1 million in the 2024 fourth quarter TTM period to US$28.9 million in the 2025 third quarter TTM period, while trailing net income moved from a loss of US$306.3 million to a loss of US$722.2 million,...

AtaiBeckley (ATAI) has drawn investor attention after receiving FDA support to advance BPL-003 into planned Phase 3 trials for treatment resistant depression and reporting positive Phase 2a data for EMP-01 in social anxiety disorder. See our latest analysis for AtaiBeckley. Despite the recent clinical momentum, AtaiBeckley’s 1 day share price return of a 4.24% decline and 30 day share price return of a 10.08% decline suggest fading near term momentum. In contrast, its 1 year total shareholder...

In February 2026, Sempra reported fourth-quarter and full-year 2025 results, issued long-term earnings guidance through 2030, and raised its quarterly dividend to US$0.6575 per share, equivalent to US$2.63 annually. The combination of multi-year EPS targets and a higher dividend offers investors clearer visibility into Sempra’s earnings trajectory and capital-return intentions. Next, we’ll examine how Sempra’s new long-term EPS guidance reshapes the company’s investment narrative and...

W&T Offshore (WTI) just posted third quarter FY 2025 revenue of US$127.5 million with a basic EPS loss of US$0.48, extending a run of unprofitable results that has investors watching the income line closely. Over the past year, the company has seen trailing twelve month revenue hover around the US$500 million mark, while trailing basic EPS has moved from a loss of US$0.59 to a loss of US$0.99. This underscores that earnings pressure remains firmly in place even as production and pricing shift...

HCA Healthcare (HCA) stock is drawing fresh attention after the company raised its 2026 guidance for revenue, adjusted EBITDA, and diluted EPS, supported by a planned $10b share repurchase and a higher dividend. See our latest analysis for HCA Healthcare. The raised 2026 guidance and capital return plan sit alongside a firm share price that is up 8.66% over the past month and 11.59% over the past 90 days. The 1 year total shareholder return of 63.38% and 5 year total shareholder return of...

Mach Natural Resources (MNR) is heading into a closely watched March 12 earnings release, with analysts expecting higher revenue but a year over year earnings decline and recently raised EPS estimates. See our latest analysis for Mach Natural Resources. At a latest share price of $13.26, Mach Natural Resources has a 30 day share price return of 7.54% and year to date share price return of 17.87%. The 1 year total shareholder return of 10.64% points to momentum that has been building ahead of...

Why Target stock is drawing attention now Target (TGT) is back on many investors’ watchlists after recent share price moves and fresh fundamental data, prompting a closer look at how its current valuation lines up with its retail footprint. See our latest analysis for Target. Recent trading has been choppy, with a 1-day share price return of a 0.54% decline contrasting with a 90-day share price return of 28.33%. The 1-year total shareholder return sits at 10.36% and the 5-year total...

Escalating conflict in the Middle East has pushed crude oil and petrochemical feedstock prices higher. Element Solutions (ESI) was caught in a sector wide sell off as investors reassessed potential margin pressure. See our latest analysis for Element Solutions. Beyond the immediate shock from higher feedstock costs, Element Solutions’ 1-day share price return of 5.01% partly offset a 7-day share price decline of 6.95%. Its 90-day share price return of 22.37% and 1-year total shareholder...

Packaging Corporation of America (NYSE:PKG) announced the retirement of a long serving board director, prompting changes at the governance level. The company promoted Fabian C. Strauss to a senior finance leadership role, bringing prior experience from large corporations into its executive ranks. A class action lawsuit was filed in California alleging violations of state labor code requirements related to employee rest periods. For investors watching NYSE:PKG, these updates come with the...

Teekay Tankers (TNK) is back in focus after brokerages lifted their current year earnings estimate by 31.5% and issued largely positive recommendations, prompting many investors to reassess the stock’s recent performance and valuation. See our latest analysis for Teekay Tankers. The latest move in Teekay Tankers’ share price to US$74.38 comes after a 3.58% 1 day share price return and sits against a 30 day share price return of 11.45%, a 90 day share price return of 38.12% and a 1 year total...

Yum China recently reported past fourth-quarter 2025 results that exceeded earnings and revenue estimates, underpinned by strong KFC and Pizza Hut performance, a focus on innovation and efficiency, and plans to open over 1,900 net new stores in 2026 while returning US$1.50 billion to shareholders. This combination of robust operating execution and sizeable capital returns highlights Yum China’s ambition to balance rapid footprint expansion with meaningful cash distribution to...

In late February 2026, Merck reported multiple pivotal Phase 3 successes across oncology and HIV, including KEYTRUDA- and WELIREG-based regimens in renal cell, ovarian and bladder cancers, alongside positive data for its once-daily doravirine/islatravir HIV pill and new FDA and EMA regulatory steps. Together with fresh AI-driven precision oncology collaborations and large-scale U.S. manufacturing commitments, these results highlight how Merck is working to broaden its portfolio beyond...

Korn Ferry (KFY) has put another solid quarter on the board, with Q2 2026 revenue of US$721.7 million and basic EPS of US$1.38 setting the tone for its latest earnings update. The company has seen revenue move from US$668.7 million and EPS of US$1.12 in Q3 2025 to US$721.7 million and EPS of US$1.38 in Q2 2026, while trailing twelve month EPS reached US$5.01 on revenue of about US$2.8 billion, giving investors a clearer read on how profits are tracking through the cycle. With earnings up 6.1%...

Global Business Travel Group (GBTG) just posted its FY 2025 third quarter numbers, with revenue at US$674 million, basic EPS of US$0.13 loss and net income of US$62 million loss. The company has seen quarterly revenue move from US$625 million in the second quarter of FY 2024 to US$591 million in the fourth quarter of FY 2024, then to US$621 million and US$631 million in the first and second quarters of FY 2025, while EPS shifted from US$0.06 in the second quarter of FY 2024 to US$0.03 loss in...

Coca-Cola (NYSE:KO) has elected Todd Beiger as vice president, signaling a change within its senior leadership team. Several top executives have recently executed substantial insider stock sales. The Board has approved Coca-Cola's 64th consecutive annual dividend increase, extending its long dividend track record. Coca-Cola, trading at around $77.8, comes into these leadership and governance updates with solid long term share price performance, including a 75.7% return over 5 years and...

Nektar Therapeutics recently faced multiple securities class action filings and investigations alleging misleading disclosures around enrollment protocols and outcomes in its REZOLVE-AA Phase 2b trial, which previously failed to reach statistical significance. These legal challenges focus on whether management accurately represented the integrity of a key clinical program, raising fresh questions about governance, disclosure practices, and oversight of trial execution. We’ll now examine how...

Recent performance snapshot for HCI Group stock Without a specific news announcement driving the move, HCI Group (HCI) has been trading with mixed returns recently, including a 3.3% decline over the past week and a small gain over the past month. See our latest analysis for HCI Group. That recent 1-week share price return of negative 5.7% sits against a year-to-date share price return of negative 10.9%. At the same time, the 1-year total shareholder return of 23.7% and 3-year total...

Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term prospects. See our latest analysis for Cytokinetics. Those fourth quarter numbers, the Myqorzo launch and the recent shelf registration filing have all come against a backdrop of relatively steady trading, with a 1 day share price return of 3.33% and a much stronger 1 year total shareholder...

Insider buying, earnings surprise and auditor change put Healthcare Realty Trust in focus Healthcare Realty Trust (HR) has drawn fresh attention after a Q4 2025 earnings beat coincided with insider share purchases by senior leaders and an auditor switch to Deloitte & Touche LLP. See our latest analysis for Healthcare Realty Trust. The share price has started to reflect this improving narrative, with an 8.9% 1 month share price return and 7.7% 3 month share price return helping lift the 1 year...

Why the latest CEO share purchase matters for Tutor Perini (TPC) The fresh insider buying by Tutor Perini (TPC) CEO, following a turnaround year in profitability, puts extra attention on the stock as investors weigh new earnings guidance and a recently affirmed quarterly dividend. See our latest analysis for Tutor Perini. After a sharp run that has produced a very large 3 year total shareholder return of more than 9x, recent trading has cooled, with a 30 day share price return of 13.7% and a...

Archer Aviation (ACHR) has just cleared a key regulatory hurdle, receiving final FAA acceptance of 100% of its Means of Compliance. This milestone moves its eVTOL ambitions closer to potential commercial operations. See our latest analysis for Archer Aviation. Despite the FAA milestone and recent news around earnings, conference appearances, and fresh equity financing, Archer Aviation’s share price return has been weaker in the short term. The stock has shown a 16.8% 7 day share price decline...

If you are wondering whether Wix.com at around US$93.89 is a bargain or just fairly priced, you are not alone, and this article is built to help you assess that question calmly and clearly. The stock has seen sharp swings recently, with a 29.4% return over the last 7 days and 24.5% over the last 30 days, set against a 7.0% decline year to date and a 44.9% decline over the past year, plus a 68.8% decline across 5 years and a 9.0% return over 3 years. These moves have put Wix.com back on many...

In late February, Tenable Holdings filed a US$135.12 million shelf registration related to 7,699,248 shares for an employee stock ownership plan, and earlier analyst commentary highlighted both its strong position in vulnerability management and rising competitive and demand concerns. While Tenable is presenting at the 3rd Billington State and Local CyberSecurity Summit today in Washington, D.C., investor focus is increasingly on how weak billings, slowing projected revenue growth, and flat...